Cargando…
Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report
Immunotherapy has been recommended as a second-line treatment only for high microsatellite instability or DNA mismatch repair deficiency advanced pancreatic cancer in National Comprehensive Cancer Network guidelines. Here, we report a case with a good response to immunotherapy in pancreatic cancer w...
Autores principales: | Chen, Mengni, Yang, Shengli, Fan, Li, Wu, Lu, Chen, Renwang, Chang, Jian, Hu, Jianli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830947/ https://www.ncbi.nlm.nih.gov/pubmed/31609933 http://dx.doi.org/10.1097/MPA.0000000000001398 |
Ejemplares similares
-
Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017) -
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023) -
Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002) -
Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
por: He, Yinjun, et al.
Publicado: (2023) -
Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)